PROPELL HOLDINGS LIMITED logo
PHL
Financial Services

Propell Holdings

Short interest
0.00%
as of 31 Oct 2024
Reported shorts
1.4K
Shares on issue
278.338M

Propell Holdings (PHL) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine
Neutral
26 Aug

What Is Driving Pharmaxis (ASX:PHL) Clinical Progress?

Highlights Pharmaxis is an Australian clinical-stage pharmaceutical company focused on developing treatments for inflammatory conditions and fibrosis. The company's LOX inhibitor platform targets the enzyme systems involved in fibrosis the scarring process that underlies conditions including liver cirrhosis and lung fibrosis. Pharmaxis generates commercial revenue from its Bronchitol product for cystic fibrosis and its dry powder technology manufacturing services. Pharmaxis Limited (ASX:PHL)...